Current best evidence on prescribed drugs

Drugdocs Logo

Current best evidence on prescribed drugs

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Tepezza

Chemical Nameteprotumumab-trbw
Dosage FormInjection (intravenous; 500 mg/vial)
Drug ClassMonoclonal antibodies
SystemEndocrine
CompanyHorizon Therapeutics
Approval Year2020

Indication

  • For the treatment of Thyroid Eye Disease
Last updated on 3/24/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Tepezza (teprotumumab-trbw) Prescribing Information.2020Horizon Therapeutics USA Inc., Lake Forest, IL
Document TitleYearSource
Comparative effectiveness of different treatment modalities for active, moderate-to-severe Graves' orbitopathy: a systematic review and network meta-analysis. 2021Acta Ophthalmologica
Treatment strategies for Graves’ ophthalmopathy: a network meta-analysis. 2020British Journal of Opthamology
Document TitleYearSource
The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy. 2021European Journal of Endocrinology